Measurement of serum adropin levels in chronic renal failure patients receiving routine hemodialysis treatment

The significance of adropin levels in chronic renal failure patients has not yet been established. This study's objectives were to compare serum adropin levels in hemodialysis patients with chronic renal failure and healthy patients as well as the clinical parameters corresponding with the levels. The total sample comprised of 49 hemodialysis individuals and 36 controls. We measured serum adropin concentrations using enzyme-linked immunosorbent assay method and analyzed various biochemical parameters including creatinine, uric acid, C-reactive protein, albumin, parathyroid hormone, and hemoglobin levels. In the patients there were statistically significant lower levels of serum adropin determined at 522.7 ± 169.4 versus 789.6 ± 259.3 ng/L, P < .01. Strong negative correlations were observed between adropin levels and both creatinine (r = -0.613, P < .001) and parathyroid hormone (r = -0.621, P < .001). Additionally, moderate positive correlations were found with albumin (r = 0.534, P < .001) and hemoglobin (r = 0.445, P < .001). There were also statistically significant differences in hemoglobin A1c of the patients and control populations with levels of 5.7 ± 1.8 versus 5.2 ± 0.5, P = .04 and C-reactive protein levels of 21.8 ± 28.9 versus 1.4 ± 2.6 mg/L, P < .01 respectively. These findings suggest that reduced adropin levels in hemodialysis patients are significantly associated with markers of renal dysfunction, inflammation, and nutritional status, indicating its potential role in the pathophysiology of chronic renal failure.